Antagonistic effect of aspartate-β-hydroxylase on chemotherapeutics in cholangiocarcinomatextCao, KevincreatorWands, JackAdvisorHuang, Chiung-KueiReaderLi, Ji SuReaderBrown University. Department of Molecular Pharmacology, Physiology and Biotechnologysponsor2019, 37 p.born digitalThesis (Sc. M.)--Brown University, 2019thesesBile duct cancer, known as cholangiocarcinoma (CCA), is a rare but highly aggressive cancer with a 3% incident in all gastrointestinal cancers. The only known curative treatment for CCA is surgical resection at an early stage, however, CCA is usually asymptomatic until advanced local or metastatic stages where surgical resection may not be considered curative or possible therapy. Aspartate-β-hydroxylase (ASPH) is a type 2 transmembrane protein that is frequently found to be upregulated in a number of cancers including CCA. The expression of ASPH has been associated with a poorer prognosis and a worse response to chemotherapy. Here, we examine the role of ASPH in chemotherapy and how it influences the DNA damage response.DNA damageBile ducts--CancerASPHEnglishRPB2019060310.26300/e9nv-a670In CopyrightCollection is open for research.